The treatment of patients with metastatic breast cancer is palliative rather than curative. In treating patients with chemotherapy, clinicians have to carefully weigh the benefits against the side effects. We have treated 76 patients with single agent mitozantrone with an overall objective response rate at 6 months of 15%. A further 22% had static disease for a minimum period of 6 months. Side effects were acceptable. All 76 patients had received at least one hormonal therapy and 30 patients had previously received ifosfamide. Previous ifosfamide therapy gave no indication whether an individual patient would respond to mitozantrone.
Adriamycin as a single chemotherapeutic agent in the treatment of advanced breast cancer has a reported response rate between 38-50%. The rate of response for mitozantrone ranges from 4-44% with a reported mean of 17% (Leyden et al., Aust. N.Z. J. Surg., 54, 21, 1984) . Our response rate lies at the lower end of this range, although with less side effects than adriamycin at standard dose. Chemosensitivity is often assumed to be related to the concentration of drug achieved in tissue, however little is known about the relative sensitivities of breast carcinomas and normal breast tissues to cytotoxic agents. In this study we have compared doxorubicin (DOX) concentrations in paired samples of tumour and normal breast from 21 previously untreated patients, undergoing mastectomy. The relative cellularity of tumour and normal tissue was estimated from the DNA content of both. We have correlated tissue drug levels with serum pharmacokinetic parameters, and also with other known prognostic factors for breast cancer such as ER status and histological grade.
Patients received (25 mg) i.v. DOX, -1 h before removal of the breast (actual times 60 + 10 min s.d.) and serum samples were taken at 5, 15, 30, 60 min. Doxorubicin concentrations from serum and tissue were determined by HPLC and DNA content by Burton's method.
There was wide variation in intra-tumoral DOX concentrations (range 220 ng g-1 to 1,590 ng g-1). Normal tissue also showed a wide variation (range 81 ng to 1,000 ng). In all cases except one, tumour levels were higher than normal tissue levels for a single patient (tumour: normal ratio range 1.27 to 8.30). When DOX was expressed in terms of weight of DNA the tumour and normal drug concentrations were similar (tumour to normal ratio range 1.1 to 1.8). Tissue DOX concentrations (both tumour and normal breast) correlated with peak serum values (P < 0.05). These findings suggest that, although there is interpatient variation in tissue levels, drug concentrations in tumour and normal breast are similar in a single patient.
Nigeria and indeed Africa remains today the greatest repository of advanced breast cancer. Some cancer patients from Africa seek treatment in Europe and America where chemotherapy is given using Caucasian standards. Fifty-four Nigerians with advanced breast cancer were treated with standard schedule of cyclophosphamide, methotrexate and 5-fluoro uracil (CMF) on out-patient basis. The dose of all chemotherapy drugs was reduced in any subsequent cycle by 30% with moderate toxicity (WBC <3,000 mm -3; platelet < 100,000 mm 3) or 50% with severe toxicity (WBC < 2,000 mm -3; platelet < 75,000 mm-3). The mean total dose received was calculated as a percentage of the standard dose for each patient over a 6 month period.
The patients, aged between 25 and 69 years (mean 47 years) had inoperable Stage III disease (26 patients) , Stage IV disease (10 patients) or recurrent/metastatic disease after mastectomy (18 patients). Only 2 patients (4%) were able to receive over 85% of the calculated standard dose, while 43 (80%) received less than 65% of the calculated standard dose. The maximum tolerance dose in Nigerians is much lower than in their Caucasian counterparts although comparable figures were obtained for objective response rate (47%); median duration of response (7 months) and median survival (9 months). Leukopenia (WBC <2,500) occurred in 48% during the first course and in subsequent courses in an additional 21% of patients. Three patients (6%) died of chemotherapy related causes all during the first course. The normal leucocyte count is lower in Africans and malnutrition, infections and infestations are rampant. The HMFG2 antigen is variably expressed and may be of prognostic significance in cancers of the lung and breast. It is also expressed variably on the cell surface of ovarian cancer primary tumours and is shed into the serum, a potential target for disease monitoring and therapy. Careful evaluation of the immunoreactivity among the histological subtypes of ovarian cancer is thus important and may provide prognostic information. We have looked at HMFG2 expression in a variety of formalin-fixed primary tumours of ovarian epithelial origin and related antigen expression to differentiation and to survival. Using a standard PAP technique tissue sections were assessed and scored by two observers for extent of staining, 0, < 50% and > 50% staining. 0  1  0  2  0  0  0  0   <50  1  3  3  0  3  1  4  >50  3  10  4  1  2  0  0 aWD=Well differentiated. bPD =Poorly differentiated.
The majority of ovarian cancer primaries exhibit HMFG2 but unlike Ward et al., (Cancer, 60, 787, 1987) the series shows that poorly differentiated serous carcinomas exhibits marked expression of HMFG2 in contrast to the other serous types. Other histopathological groups do not show such a consistent pattern. Within a single specimen heterogeneity of staining was seen. Regardless of therapy, the survival of patients who express HMFG2 strongly (>50%) was worse than those who expressed it poorly (<50%) respective survival times being 11 months and 16 months (P=0.01, Mann-Whitney U). Further data accrual will be required to verify this finding. In premenopausal women with advanced breast cancer the luteinising hormone releasing hormone (LHRH) zoladex produces response rates similar to surgical oophorectomy. There have been proposals both to use zoladex as adjuvant therapy and in benign disease: irreversible ovarian suppression would be an unwanted side effect in these patients. We have looked at the histological changes in the ovaries of patients with advanced breast cancer treated by zoladex.
In a phase I clinical trial of zoladex as first line hormonal therapy in premenopausal women with advanced breast cancer, patients on progression of their disease underwent surgical oophorectomy. The histology of 39 ovaries from 23 women treated with zoladex (Zx) has been compared to 68 ovaries from 34 patients who underwent surgical oophorectomy as primary therapy (Ox).
Histologically both the Zx and Ox groups show similar follicular phase development. Follicular cysts were seen more often in the ovaries of Zx treated patients than in the Ox patients (P < 0.05). Corpus lutea were seen more often in the ovaries of Ox patients than in the Zx patients (P<0.01).
Zoladex appears to arrest development of follicles with formation of follicular cysts. Despite low FSH levels folliculogenesis was not inhibited.
Oestrogen and progesterone receptors in ovarian cancer M. Harding', S. Cowan2, L. Cassidy3, H. Kitchener3 & R.
Leake2
Departments of IMedical Oncology, 2Biochemistry and 3Gynaecology, University of Glasgow, UK.
The prognostic significance of steroid receptors in breast cancer is well recognised. To determine whether expression of receptors is a biological marker of less aggressive disease in gynaecological cancer, quantitation of oestrogen (ER) and progesterone (PR) receptors has been carried out over the last 4 years. Soluble and nuclear receptor levels were determined by Scatchard analysis: tissue samples were defined as positive if soluble ER and/or PR levels exceeded 10fmolmg-1 protein with nuclear levels >150fmolmg-DNA.
The majority of benign ovarian cysts (14/15) and borderline malignant tumours (2/2) were ER-PR-: both (2/2) granulosa cell tumours were ER+ PR+. Of the 66 samples from patients with non-pretreated epithelial ovarian cancer, 18 were ER+ PR+ (27%), 15 were ER+ PR-, 5 were ER-PR+ and 28 were ER-PR-(42%); approximately 10% of each subgroup were premenopausal. FIGO Stage I and II tumours were more commonly PR+ (10/23) than PR-(4/43) but there was no association between early stage and ER status .
Survival of patients with advanced disease (FIGO Stages III or IV) indicates that expression of steroid receptors may be of prognostic significance though data are preliminary. Median survival (in months) according to receptor There is considerable experimental evidence that verapamil can overcome adriamycin resistance in a variety of experimental tumour models. Following a suggestion made by Durie and colleagues that this phenomenon might be applied to patients with myeloma, we have conducted a study on 7 myeloma patients with acquired or primary resistance to the VAMP regimen (vincristine 0.4mg daily, adriamycin 9mgm-2 both by continuous infusion for 4 days, methylprednisolone 1 gm-2 IV orally daily for 5 days repeated every 3 weeks). Four patients were treated with VAMP to a plateau phase i.e. after achieving the maximum reduction in paraprotein no further response to VAMP was seen. Three patients had primary VAMP-resistant disease. These 7 patients were all treated with verapamil (10mgday-1 by continous infusion for 5 days) together with further treatments with the VAMP regimen. In 4 out of 7 patients the treatment produced further reductions in the paraprotein levels of >25%. In 2 of these patients, the paraprotein fell by >50% and in one case the paraprotein became unmeasurable. Two of the responders to initial observations support the hypothesis that verapamil can overcome some of the mechanisms of resistance to adriamycin and vincristinecontaining regimens in patients suffering from myeloma. Further studies to elucidate its precise role in the management of myeloma patients treated on this and similar schedules are indicated. Mitomycin, ifosfamide and cisplatin are three of the most active single agents in the chemotherapy of non-small cell lung cancer. We have combined them in a 24 h schedule ('MIC') for a phase 2 study in patients with inoperable nonsmall cell lung cancer. The regime consists of: mitomycin 6mgm-2 i.v. bolus, ifosfamide 3 gm-2 i.v. infusion over 3h and cisplatin 50 mgm-2 i.v. infusion over 1 h. Mesna is given with the ifosfamide infusion at a dose of 1 gm-2 and a further 500 mgm-2 bolus is given 3 h later followed by a 6 h infusion (500 mg m 2). The anti-emetic regime consists of lorazepam 2 mg m-2 dexamethasone 8 mg m-2 and metoclopramide 1 mg kg-1 i. There was no significant correlation between the severity of hearing loss and the number of days of other ototoxic treatment, the total dose and the number of courses of cisplatinum, and the age at the start of treatment. There was no significant difference in hearing loss between children receiving high dose (200 mg m 2) and those receiving conventional dose (75-125 mgm-2) cis-platinum.
Five of 7 children who had follow-up audiometry continued for more than a year after the end of treatment showed some reversibility of hearing loss (defined as an improvement of 15 dB or greater) in at least one ear.
This study demonstrates that ototoxicity is a significant adverse effect of cis-platinum, but further follow-up is needed to determine how much recovery may occur. No increase in toxicity occurred with use of high dose cis-platinum. Gut damage during the treatment of childhood acute lymphoblastic leukaemia
Departments of 1Child Health and 2Clinical Biochemistry, University of Newcastle upon Tyne, UK.
Gut toxicity in patients receiving treatment for childhood acute lymphoblastic leukaemia (ALL) is assuming greater importance as new intensive strategies are being used. Recent retrospective reviews show that following consolidation therapy of ALL 38% of patients develop gastrointestinal toxicity and 25% of these develop persistent intestinal damage. At present it is impossible to predict prior to therapy which children will develop these complications. In an attempt to identify those children at greatest risk of gut toxicity a cohort of children undergoing intensive therapy for childhood ALL have been studied sequentially. Small intestinal mucosal function has been assessed by a novel intestinal permeability test. Three non-metabolised sugar markers were administered in a oral solution of 696 mOsm kg -I containing 4mg m 2 mannitol (M), 4mg m-2 lactulose (L) and 1.6 mgm-2 of 3-0-methyl-glucose (MG). Children with ALL were studied prior to and weekly on 5 occasions after intensification therapy. Two weeks after chemotherapy M, MG and L absorption was impaired compared to controls and values before consolidation (P=0.02 and P=0.05). This was followed by gradual recovery which reached normal levels by 5 weeks in the majority of children. However in some children recovery of sugar permeation did not occur. Longitudinal studies revealed that these children developed persistent enteropathy with malabsorption.
Studies are now in progress to identify the clinical and nutritional characteristics of those children who developed gut toxicity. By these means it may be possible to identify those children at greatest risk of gut damage and to develop methods of intervention to prevent toxicity.
Evaluation of simultaneous four-parameter flow cytometry for the screening of samples from the uterine cervix
Departments of 'Immunology and 2Morbid Anatomy (Cytology), King's College School of Medicine and Dentistry, London SE58RX, UK.
The purpose of this study is to investigate the role of multiparametric flow cytometry in the identification of the normal population in a cervical screening programme. Using samples from normal and at-risk patients we are simultaneously analysing DNA content, cell markers, cell volume and wide angle light scatter. A fixation regime has been established allowing staining of nuclear DNA by propidium iodide without removal or alteration of the cell surface and without a change in cell volume. A previous immunohistochemical study, using an antibody to the transferrin receptor, showed positive staining with the majority of tumours and severe dysplasias and the complete absence of staining with normal epithelia suggesting that this antibody may distinguish between normal and neoplastic cells (Lloyd et al., J. Clin. Path., 34, 131, 1984) . This antibody is now being used in flow cytometry although other markers are being investigated.
The most effective combination of parameters giving rise to no false negative results is being established and this combination will be used to identify normal specimens. Data from 2,000 cervical samples will be reported comparing flow cytometry with routine cytology.
Application of multiparametric flow analysis as a primary screening procedure will drastically reduce the labour content associated with the examination of normal smears which form at least 70% of the samples processed by most routine cytology laboratories. Quantitation of the metabolites of oxazaphosphorine drugs such as ifosfamide (IF) is important in understanding both the efficacy and toxicity of the drug in individual patients. IF and its principal metabolites were determined by highperformance thin layer chromatography-densitometry (HPTLC-PD) in 0-24 h urines from 18 NSCLC patients who had been given IF (1.5 gm 2) either orally or intravenously.
On HPTLC-PD, Rf values for the various metabolites were: IF (0.70), the two dechloroethyl metabolites (0.47), carboxyifosfamide (0.33), 2-chloroethylamine (0.10) and isophosphoramide mustard (0.02). At high concentration it was sometimes difficult to separate these last two alkylating metabolites; they were thus estimated conjointly. 316, 899, 1987) .
To avoid multiple leukophoresis for in vitro generation of LAK cells and to reduce toxicity, recombinant IL2 (rIL-2) was given as a first dose via an intra arterial catheter into the spleen, followed by 4 i.v. doses on alternate days. A total of 3 courses were planned at 3 week intervals. The maximum tolerated single dose was 11 x 106 CetusUUm-2. Thirty patients with progressive metastatic malignant melanoma entered the study; in 4, treatment is still ongoing. Four patients showed a PR, 5 have stable disease.
The PBMC of all patients tested contained LAK precursors estimated by in vitro rIL2 induction of cytotoxicity against NK- The majority of superficial bladder cancers recur, and 10-20% progress to muscle invasion. The course of the disease usually is prolonged, but regular (3-12 month interval) cystoscopic review is required, and a reliable predictor of either recurrent superficial or muscle-invasive disease would improve patient management. DNA ploidy was measured by flow cytometry using nuclei extracted from paraffin sections in an unselected series of 136 biopsies from 100 patients presenting in [1978] [1979] Optimal membrane fluidity is an important factor in cell physiology and is dependent mainly on the degree of fatty acid desaturation of the lipids in the membrane bilayer. Significant changes have been reported in the saturation of fatty acids, predominantly in the ratio of stearic to oleic acid, in erythrocyte cell membranes of cancer patients (Wood et al., Br. Med. J., 291, 163, 1985) . This ratio is referred to as the saturation index (SI).
In this study, the lipid analysis of peripheral blood cells from patients with AIDS (n = 12) and control subjects (n=24) was investigated by gas liquid chromatography.
The SI was significantly lower (P <0.0001) in AIDS patients (means: RBC=0.18; WBC=0.11) compared to the controls (means: RBC = 1.03; WBC= 1.40). This suggests the HIV could be responsible for the low SI seen in peripheral blood cells of AIDS patients. It is also interesting that the index is differentially lower in the WBCs, the target cells of the AIDS virus.
This desaturation of peripheral cell membranes could partly explain the systemic metabolic disturbances seen in this infection. (1983, 1986) with the difference that CT was continued for only two courses (one full cycle) beyond marker remission with a minimum of 5 courses. Intrathecal methotrexate was given to only one of the patients with cerebral metastases (mets) and none received XRT. Tumour masses remaining after CT were resected if possible.
The median number of courses of CT received by patients completing treatment was 6 (range 5-13 Glasgow data show that patients with very high volume metastases (MRC definition) from testicular germ cell tumours or extragonal primary sites, have 2 year survival rates of 58% and 25% respectively. This pilot study was designed to improve these results. To date 27 patients (median age 33 years) have completed therapy with nodal disease > 1O cm (n = 7), advanced pulmonary metastases (number >20 and/or >3 cm: n = 4), brain (n =1), bone (n = 1) or liver (n = 4) involvement or extragonadal primary sites (n = 10: all with lesions > 7 cm). Twenty-three of 24 patients with teratoma were marker producing: median HCG level 93,750u1 ' (561-1.6x 106), median AFP6, 170uml (125-73, 800).
Treatment comprised 3 cycles of CDDP 50 mgm 2 days 1 and 2 with vincristine 2 mg and bleomycin 30 mg day 1 at 7-10 day intervals (BOP): then 3 courses of CDDP 20mgm 2, ifosfamide 1.2mgm-2 days 1-5 with VP16 75-100mgm-2 days 1, 3, 5 (VIP) q 3 weekly. Grade 4 myelotoxicity necessitated reduction in VP16 dosage in 7 of 10 patients receiving 100mgm-2: 2 septicaemias occurred. Toxicity requiring protocol modification was neuropathy (n=2) and renal failure (n=1); 3 patients developed significant neuropathy after completion of BOP/VIP. required. From 1983 required. From to 1987 patients (10 females and 5 males), with metastatic adenocarcinoma of unknown primary origin was treated with BEP, bleomycin 30mgday-1 i.v. infusion days 1-3, cis-platinum 40 mgm 2 i.v. days 1-3, etoposide 120mgm-2 i.v. days 1-3, repeated every 21 days, at least 3-4 courses were given to each patient.
The median age of the patients was 38 years with a range between 22-44 years. At presentation the sites of metastasis in patients were lung 12, liver 6, bones 7, brain 2, lymphnodes 5, skin 1 and fundus 2. Two of 15 patients had disease confined to the lung, one confined to the bone, and one to the pelvis. Alpha-foetoprotein and HCG levels were normal in all patients. Fourteen of 15 patients had poorly differentiated or undifferentiated adenocarcinoma and one patient had a well differentiated tumour. Five of 15 patients (2 CR, 3 PR) responded to therapy, 6 of 15 patients were unresponsive, and there were 4 of 15 early deaths (after one cycle of treatment). One patient with CR relapsed 2 months after completion of therapy, and the other patient having had previous radiation to the chest died in CR due to bleomycin toxicity. Two of 15 patients are alive (1 PR, 1 fail) at the time of the report. Lung toxicity was observed in 6 of 15 patients (assessed by PFT and chest X-ray) and in 1 patient it was fatal. Renal toxicity was observed in 4 of 15 patients and in 2 of 15 it was fatal. Post mortem examination was performed in 6 of 15 patients: 3 patients had a primary tumour in the lung, I patient died of severe bleomycin toxicity (having had previous chest irradiation) without any residual tumour detected, and in 2 patients a primary site could not be located. This regime was considerably more toxic in this group of patients than in the younger patients with teratoma receiving the same regimen, and there were no long-term survivors.
A randomised double-blind cross-over trial of dexamethasone and lorazepam with or without high dose metoclopramide infusion in the treatment of chemotherapy induced emesis High dose metoclopramide (MET) is an effective anti-emetic for use with cis-platin containing chemotherapy regimens but can cause extrapyramidal reactions (EPR). Lorazepam (L) and dexamethasone (D) are being used increasingly to alleviate chemotherapy induced emesis. This trial addresses the question 'does high dose MET contribute to anti-emetic control when given with dexamethasone and lorazepam? Eighty-one patients have entered a randomised double blind cross over trial comparing lorazepam and dexamethasone with or without high dose MET. Lorazepam 2 mgm-2 was given with dexamethasone 8 mg i.v. and either MET 1 mg kg-I or a placebo of N Saline 60 min before chemotherapy. This was followed by a 24 h infusion of MET 9 mg kg 1 or placebo with 4 mg boluses of dexamethsone 4 hourly i.v. If there is no vomiting patients then receive oral dexamethasone 4 mg qds plus either MET 20 mg qds or placebo tablets for 3 days. Patients were crossed over for the second course of treatment and then chose their preferred regimen for subsequent treatments. Randomisation was stratified according to whether or not the patient will be receiving cis-platin. Fifty-four patients are assessable having completed two courses and stated a preference, 29 received LD Met first and 25 LD Plac first. The chemotherapy regimens were given for a range of gynaecological and other malignancies, 48 contained cis-platin and 6 non-cis-platin regimens. The mean number of episodes of vomiting during the first 24h for first and second courses (see Table) was significantly fewer when receiving LD Met than with LD Plac (P<0.0001).
The difference in nausea control also significantly favoured the 3 drug regimen (P <0.0004). Thirty-six patients with apparent stage I non-seminomatous germ cell tumour (NSGCT) of the testis were treated by inguinal orchidectomy and intensive follow-up only. Assessment included measurement of serum alphafetoprotein and beta HCG (tumour markers) and chest X-ray monthly for 1 year, then 2 monthly for 1 year, with CT scans of abdomen and chest repeated 3 monthly for the first year and 6 monthly for the second year. Median follow-up was 33.5 months (range 5-87 months). Relapse occurred in 12 patients (33.3%) at a median of 7 months (range 2-28 months). A further patient developed a pure seminoma in the other testis at 15 months and another had a para-aortic mass detected on CT scan at 15 months. Laparotomy was performed and histology revealed a differentiated teratoma. Elevated markers were of limited importance in relapse detection confirming the need for close clinical and radiological follow-up. Of 9 histological factors examined in the primary tumour only the presence of lymphatic invasion was associated with a significantly higher relapse rate. All patients were treated at relapse with cis-platinum based chemotherapy. Four underwent surgery in addition, 2 before and 2 after chemotherapy. Eleven were rendered disease free but 4 had a second relapse. One patient has died, one is alive with disease in fourth relapse, and 10 are disease free. Chemotherapy failed to cure 6 patients who had relapsed, but bulk of disease was not a factor. Despite the good overall result reported here, optimal post-orchidectomy management of stage I disease remains to be defined. Recently we reported an inverse association between HMFG2 antigen expression and survival in SCLC patients (Allan et al., Br. J. Cancer, 56, 485, 1987) . We have now extended the preliminary study of HMFG2 expression in pre-treatment bronchial biopsies to include a further 21 patients, making a total of 52 tumour specimens. As before, formalin fixed, paraffin embedded material was studied using a standard immunoperoxidase (PAP) staining procedure following enzyme digestion of the tissue sections.
Overall, median survival was 8 months for those expressing HMFG2 antigen compared with 11 months for those who were negative (P<0.01 Mann-Whitney U). In the group of patients with limited disease (n = 40), the same statistical difference was apparent with median survival of 8 months in 22 patients who were positive for HMFG2 and 12 months for the 18 patients who were negative (P<0.01). The value of HMFG2 as a prognostic marker merits study in a wider assessment of pre-treatment prognostic variables. Retrospective analysis of 133 patients with multiple myeloma treated at our district general hospital over the last 14 years was undertaken.
All patients presenting with stage 3A (13 patients) or stage 3B (24 patients (with renal impairment)) disease, according to the staging system of Durie & Salmon (Cancer, 36, 842, 1975) were treated with a four drug chemotherapy regimen, given monthly and using: vincristine, 1.4 mg m-2 (max. 2mg), cytosine arabinoside, 150mgm2, cyclophosphamide 600mgm-2, all given on days 1 and 8 by i.v. bolus injection and prednisolone 30 mg m-2 orally on days I through 8, along with standard supportive measures.
Of these 37 patients 14 died early in treatment prior to receiving two courses of chemotherapy (in the first 2 months after diagnosis).
Comparison of patient groups suggests that if patients with stage 3A or 3B myeloma survive this 2 month period then their survival thereafter is the same as the prognostically more favourable groups.
This we feel favours the use of intensive supportive therapy in the management of patients who present with poor prognosis myeloma, and we would advocate the use of combination regimens which can be safely used in the context of renal impairment, and which achieve rapid tumour kill. The CMPP regime was developed for the treatment of intermediate and high grade non-Hodgkin's lymphoma stage II-IV in elderly and poor performance status patients in whom doxorubicin containing regimens would be too toxic. Twenty-one patients (9M: 12F) aged 52-79 mean 70 years, have been entered onto the study. There were 12 high and 7 intermediate grade (NCI Working Formulation) and 2 mycosis fungoides. Eighteen of 21 were stage IV and 6/16 had marrow involvement but no patient was leukaemic. Twelve (51%) had received prior treatment at a mean of 3.3 years before CMPP: 5 radiotherapy, 2 chemotherapy and 5 with both. Patients received chlorambucil 10 mg d-1 dI-O0, mitozantrone l0mgm-2 i.v. dl, procarbazine 150mgd-1 dl-10 and prednisolone 40mgd-1 dl-10, q21-28d. The mean number of courses given was 3.7 and the mean cycle time was 30d. Of 16 evaluable patients there were 6CR, 6PR, 4SD (overall RR 75%). Responders received a mean of 4.7 cycles against 2.4 in non-responders but there Was no significant difference in cycle time (31 vs. 21 d). Median follow-up is 4 m and there have been 7 deaths at 0-11 m (2 early deaths in whom toxicity may have been contributory). Median survival is 11 m. Three patients developed neutropenic fever and 2 required transfusion but grade III/IV alopecia and vomiting were not seen. Sixteen of 78 courses were deferred in 9 patients and procarbazine was omitted after the first or subsequent cycles in 6 patients due to rash in 4 and myelosuppression in 2. The CMPP regime produces an acceptable response rate in this poor prognosis group with a median survival of 11 m. The dose limiting toxicity is haematological. Since 1/84 16 patients (11 male, 5 female, age range 18-73 years, median 28 years) with poor prognosis relapsed Hodgkin's disease (HD) (<1 year post chemotherapy) have been treated with CAPE (cyclophosphamide 600mg m 2 i.v. dl; adriamycin 50mgcm-2 i.v. dl; adriamycin 50mgcm-2 i.v. dl; etoposide, either 500 mgm 2 p.o. given over d2-5 or 250mgm-2 i.v. dl) and PALE (CCNU 80mgm-2 p.o. dl, with adriamycin, etoposide and prednisolone as above) given as alternating cycles at 21 day intervals for 6 cycles. At initial diagnosis 13 patients had NSHD, 3 MCHD; 5 patients were stage II, 11 stage III and I stage IV; 10 patients had B symptoms. Twelve patients had received prior chemotherapy only, 4 radiotherapy and chemotherapy, 6 having achieved a CR lasting 2-12 mo, median 4/12, 7 a PR and 3 progressive disease on therapy immediately prior to CAPE/PALE. All patients had relapsed at previously involved sites and at new sites in 3. The mean number of cycles of CAPE/PALE administered was 5.5 (range 1 to 7). Eight patients achieved a CR of whom 4 remain free of disease at 16, 31, 33 and 42 mo, and 3 a PR an overall response rate of 69%. Toxicity has been moderate. There were 8 episodes of neutropaenic fever, two of dermatomal HZV and one each of axillary cellulitis, infected central venous catheter, acute myocardial infarction (AMI) and cryptosporidial infection. There were no treatment related deaths. Treatment was delayed in 9 patients on 16 occasions and dose reductions made in 10 patients in 31 out of 86 cycles given, in 1 patient initially due to thrombocytopaenia and later AMI and in 9 due to neutropaenia. CAPE/PALE is effective as salvage chemotherapy in relapsed Hodgkin's disease. Results are at least as good as alternative regimens with acceptable toxicity and fewer injections. months from CT, 1 during CT and 8 from HD. The regime was generally easy to administer and well tolerated. A mean of >90% of the planned dose of each drug was administered. Five patients required cessation of one of the regime's drugs and substitution with another agent because of side effects. Three patients had mild neuropathy, 2 moderate nausea, and no patient had alopecia. There were 3 episodes of neutropaenic fever, one of pneumococcal pneumonia and one of disseminated HZV. One patient died during CT from legionella pneumonia. Treatment was delayed in 8 patients on 10 occasions, 1 due to poor compliance and in 9 due to neutropaenia. Both rIFN-G and rIL-2 have shown anti-tumour activity in single agent phase I studies. In vitro studies have demonstrated synergistic anti-tumour activity. T cells activated by rIFN-G developed maximal proliferative responses to rIL-2 after 4 days exposure. This study was designed to determine the maximally tolerated dose and optimum immunomodulatory doses (OID) of 5 daily i.v. bolus (over 15 min) injections of rIL-2 following 5 daily i.m. injections of rIFN-G given in two doses (10 and 100pgm-2 day) 16 patients have been entered and recruitment will be completed in January 1988. Tumour types were: melanoma (4), renal carcinoma (4), colon carcinoma (3), soft tissue sarcoma (2), mesothelioma (2) and non small-cell lung (1). Nine patients had no prior chemo-or radiotherapy. rIL-2 dose levels were 0.5, 1.0, 2.0 and 3.Omega(m)Um-2d-1. Tengm-2 of rIFN-G gave minimal side effects and whilst 100pgm-2 gave more toxicity no unexpected problems arose. All 3 patients given 3.0mUm-2d-1 experienced WHO grade III/ IV toxicity (hypotension, fever and liver toxicity). Two required intensive care management for hypotension. 2.0mUm-2d-1 plus lOugm-2 rIFN-G could be used for phase II studies in an ordinary ward setting. So far no objective tumour responses have been seen. A recommendation for phase II will depend on toxicity in the 100ygm-2d-1 rIFN-G arm and on the OID. Immunological testing will be performed on stored frozen cells in order to ensure assay standardisation (e.g., NK and LAK cell assays). The outlook for patients with relapsed high and intermediate grade NHL (WF) and multiply relapsed HD is dismal. Evidence suggests marrow ablative CT and marrow rescue may improve survival. 'PACET' is highly marrow suppressive CT which can be given as repeated courses with acceptable and manageable toxicity without marrow rescue. Early results suggest activity in these patients. Sixteen heavily pretreated patients with relapsed high or intermediate grade NHL or HD were treated with CCNU 60 mg m-2 p.o. dl-2; cytosar 00 mgm -2 i.v. BD, VP16-213 l00mgm-2 i.v., 6-TG 80mgm-2 p.o. and prednisolone 40mgm-2 p.o. all dl-5 repeated at d28. A mean of 1.9 courses (range 1-3) were given to 14 evaluable patients with median age 46 years (range 28-65). Ten had DLC, 1 immunoblastic and I small non-cleaved lymphoma, 1 HD and 1 malignant histiocytosis. All patients had shown at least PR to prior CT. Two patients (14%) achieved CR and are disease free at 2 and 14 months. One patient had a PR lasting 6 months and is alive at 24 months. Overall response is 21%. Two further patients had stabilization of disease (s.d.) for 10 months prior to progression, 1 remaining alive for 17 months. Nine patients have died. CT was generally well tolerated with <50% patients having mild nausea and vomiting. It has been shown in several xenograft models that synergy exists between interferon and a wide variety of cytotoxic drugs. The mechanism of this is unknown but it has been speculated that interferon may alter drug biotransformation. Interferon can inhibit cytochrome P450 which is important in the biotransformation of ifosfamide to its active metabolites. We therefore, decided to investigate the effect of alpha-2 interferon on the pharmacokinetics of ifosfamide. Patients with non small-cell lung cancer were given ifosfamide 1.5 gm-2 i.v. per day for 5 days during which serial blood samples were taken for assay of ifosfamide levels. Two weeks later they were started on alpha-2 interferon 3 million units SC x 3/week for 2 weeks. During the second week, they were given a second 5 day course of ifosfamide at the same dose as before and further blood samples were taken to study ifosfamide pharmacokinetics. An objective response rate of 71% was obtained using a combination of cis-platin 100 mgmi-2, vincristine 1 mgm-2, methotrexate 300mgm-2 and bleomycin 30mg (POMB) in 24 patients with advanced squamous cell carcinoma of the cervix (Br. J. Obstet. Gynaecol., 94, 111, 1987 (Fidler, Cancer Res., 45, 4714, 1985) .
A study of liposome encapsulated MTP-PE Stage IV ovarian carcinoma (OC) has a poor prognosis. Our previous experience with cis-platinum 100 mg m-2 in 19 such patients gave a 61% response rate, a median survival of 13 months, and only one patient alive beyond 3 years (Wiltshaw et al., J. Clin. Oncol., 4, 722, 1986) . The dose limiting toxicity of JM8 is haematological which makes it attractive for use in high dosage with full support.
In an attempt to improve survival of stage IV OC we treated 38 patients with HD JM8 every 4-5 weeks (14 patients in a dose escalation study -(mgm-2) 520 (5) 650 (6), 800 (3) patients -and 24 patients at I g m-2). Median age 55 years . WHO PS 0 (12), 1-2 (20), 3-4 (6) patients. Residual bulk (cm) <2 (4), 2-5 (8), >5 (26) patients. Response, relapse and median time to relapse (MITR) as follows (3 of the 1 gm-2 patients were not evaluable for response). infusion, starting 30min post cytotoxic drug treatment. N/V were assessed on 4-point global scales, nausea was also selfassessed on a visual analogue (VA) scale and emetic episodes were recorded for 24 h after chemotherapy. Results were: cisplatin (75-100mg m2 9 patients) 1 patient had no NV, 2 were free from NV for 12-18 h, 3 had N/V but less than on previous courses and 3 all with anticipatory N/V, derived no benefit. Carboplatin (200 mg m -2, 3 patients) ( + methotrexate and vinblastine): all 3 patients had no M/V. Trimelamol 800 mgm-2 x 3, 2 patients): both patients had no benefit. Vomiting following BRL 43694 was not always associated with nausea. Using global scales 2 patients reported mild nausea at 4h and 6 patients had moderate nausea at 24h. Using VA scales moderate/severe nausea at the time of dosing was seen in 6 patients which persisted to 24 h in 4. The only side effect noted was a mild/moderate headache which occurred in 5 patients. No other adverse effects were noted. Haematology and biochemistry values stayed within normal limits and the ECG (monitored for 30 min) and blood pressure (monitored for 6 h) were unaffected. In summary 9/14 patients with severe N/V refractory to conventional antiemetics experienced benefit from low doses of BRL46394 compared to their previous courses. Six of these had a substantial improvement. Patients with anticipatory vomiting did not benefit from the treatment schedule used. UFT is a combination of uracil and the 5-fluorouracil (5-FU) analogue Futraful (1-(2-tetrahydrofuryl)-5-fluorouracil). Studies in vitro and in experimental tumour models have shown that the cytotoxic effect of fluoropyrimidines can be potentiated by purines and pyrimidines (Fukii et al., Gann, 69, 763, 1978) . The mechanism of this effect may be related to the increased intratumoral levels of 5-fluorouracil achieved with concomitant administration of uracil (Taguchi et al., Cancer Chemother., 5, 1167 , 1978 . Futraful has greater bioavailability than 5-FU after oral administration. It is metabolised to 5-fluorouracil and at least four other compounds (Au, Cancer Treat. Rep., 63, 343, 1979 CB1O-277 is an analogue of dacarbazine (DTIC) which is currently undergoing phase I clinical evaluation. In experimental systems CB1O-277 and DTIC have equivalent antitumour efficacy and CB1O-277, like DTIC, requires metabolic activation in order to display activity. As part of the preclinical and early clinical evaluation of CB1O-277 the pharmacokinetics of the drug in patients and mice have been compared. In mice, following a maximum tolerated dose (750 mgm-2 i.v.), CB19-277 was cleared monophasically from plasma (25 mlmin m-2, t2 32 min). In addition to CBIO-277 one major and two minor metabolites were found in plasma using HPLC analysis. The major metabolite was sensitive to hydrolysis by glucuronidase yielding CBIO-277 whilst one of the minor metabolites was identified by HPLC as the monomethyl derivative of CB1O-277. Monomethyl CB1O-277 is the proposed active metabolite of the drug and the levels observed in plasma (>50MM for I h) are sufficient to explain the antitumour activity seen with Urol., 133, 403, 1985) . We undertook a phase II study to confirm these results.
Treatment was M 30mgm 2 i.v. days 1, 15 and 22; V 3mgm-2 i.v. days 2, 15 and 22; A 30mgm-2 i.v. day 2; and C 70 mgm-2 i.v. day 2. Maximum of 6 cycles was given at 4 weekly intervals. If the creatinine clearance was under 40 ml min-1, C was withheld (3 patients) or carboplatin was given (4 patients) at a dose adjusted for renal function. Patients were assessed after 3 and 6 cycles of chemotherapy.
Twenty-six patients with transitional cell carcinoma (2 advanced primary cancer alone and 24 metastatic disease) were treated. Thirteen had progressed after DXT to the primary site and 2 had received prior chemotherapy. Median age was 64 years (range 34-75), 22 male and 4 female. Median ECOG status at entry was 2 (0= 5 patients, 1 = 7 patients, 2 = 5 patients, 3 = 9 patients).
Of the 26 patients assessable to date, 3 had complete response and 10 partial response. The overall response rate was 13/26 (50%) and median response duration was 30 weeks. Responses was seen in the bladder (44%) including 3 patients who had progressed after DXT, lymph nodes (68%), lung (37%) and liver (25%). There were 2 early deaths (1 toxic and 1 sudden at home). All patients are evaluable for toxicity; 11 had WHO grade III or IV vomiting and 16 had WHO grade III or IV myelosuppression.
M-VAC chemotherapy is effective in this group of poor prognosis patients with advanced bladder cancer. Toxicity is significant, but M-VAC gives useful palliation for many patients. ABMT is widely used to reduce myelosuppression after high dose alkylating agent, but often with little firm evidence of its value. We have studied haematological recovery in 31 fit, previously untreated small cell lung cancer patients receiving high dose CTX with ABMT.
Chemotherapy was CTX, either 160 mg kg-1 or
